Visioneering Technologies, Inc. (ASX: VTI) announced promising preliminary year-two results from the PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) study. Dr Ashley Tuan, Chief Medical Officer, will present these findings at the Global Specialty Lens Symposium in Las Vegas on 16 January 2025 US time.
The data demonstrates the safety and efficacy of NaturalVue lenses in controlling myopia progression in children. After two years, the adjusted treatment effect in refractive error progression was 0.60 diopters (53% reduction), and in axial length elongation was 0.25 mm (86% retardation), aligning with FDA-approved therapies for myopia control. The PROTECT study, a rigorous three-year randomized, double-masked clinical trial, reinforces real-world data and six-year studies on NaturalVue lenses. High comfort and vision performance ensure a low dropout rate, supporting their long-term usability and effectiveness.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 20, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
